文献速递特殊人群用药治疗药物监测与药物基因组学药物不良反应与药物警戒

左氧氟沙星治疗耐利福平结核在妊娠及产后的药代动力学与安全性:IMPAACT P1026s 研究结果

Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s.
PubMed 文献 · Clin Pharmacokinet · 2025-03-28

该观察性队列研究纳入11例接受含左氧氟沙星方案治疗耐利福平结核的孕妇,在妊娠中晚期及产后进行密集药代动力学采样,目标血浆浓度为7 µg/mL。结果显示妊娠中期左氧氟沙星AUC0-12低于产后,但总体暴露在目标范围内;多数妇女和婴儿发生与左氧氟沙星不太可能相关的严重不良事件。

要点

  • 妊娠中期左氧氟沙星AUC0-12低于产后,但总体暴露在目标范围内。
  • 妊娠中期、晚期和产后的中位Cmax分别为10.3、10.6和10.6 µg/mL。
  • 8例(72%)妇女和7例(64%)婴儿发生与左氧氟沙星不太可能相关的严重不良事件。

核心结论

  • 妊娠中期左氧氟沙星AUC0-12低于妊娠晚期和产后,但总体暴露在目标范围内。

研究设计与样本

  • 观察性队列研究,纳入11例妊娠中晚期并接受耐利福平结核治疗的孕妇,在妊娠20-26周、30-38周及产后2-8周进行密集药代动力学采样。

主要发现

  • 妊娠中期、晚期和产后的左氧氟沙星中位Cmax分别为10.3、10.6和10.6 µg/mL。
  • 妊娠中期、晚期和产后的左氧氟沙星中位AUC0-12分别为69.0、77.6和80.2 µg·h/mL。
  • 与产后相比,妊娠中期左氧氟沙星中位AUC较低且清除率较高,妊娠晚期无此差异。
  • 8例(72%)妇女和7例(64%)婴儿发生严重或危及生命的不良事件或结局,均与左氧氟沙星不太可能相关。

关键数值与推荐

  • 左氧氟沙星血浆浓度目标为7 µg/mL。

临床怎么用

  • 妊娠中晚期使用左氧氟沙星治疗耐利福平结核时,总体暴露可达目标范围,但妊娠中期暴露较低,需关注疗效。

局限性

  • 样本量小(11例),结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Treatment of rifampicin-resistant tuberculosis (RR-TB) often includes fluoroquinolones, but data on long-term exposure during and after pregnancy are limited. We examined the pharmacokinetics and safety of levofloxacin in an observational cohort of pregnant and postpartum women receiving treatment for RR-TB. METHODS: Participants were enrolled in their second or third trimester and underwent intensive pharmacokinetic sampling to quantify levofloxacin plasma concentrations at 20-26 weeks' and 30-38 weeks' gestation and at 2-8 weeks postpartum. The levofloxacin plasma concentration target was 7 µg/mL. Pharmacokinetic parameters over 12 and 24 h were described using non-compartmental analysis and within-participant comparison during pregnancy versus postpartum. Adverse events were extracted from medical records. Infants were enrolled in utero and followed on study for 4-6 months after birth. RESULTS: A total of 11 pregnant women, with a median age of 31 years, received RR-TB treatment including levofloxacin; 6 (55%) were living with HIV. In the second trimester, third trimester, and postpartum, median maximum plasma drug concentration values were 10.3, 10.6, and 10.6 µg/mL, and area under the concentration time curve over 12 h (AUC0-12) were 69.0, 77.6, and 80.2 µg·h/mL, respectively. Compared with postpartum, median AUCs were lower and clearance was higher in the second but not the third trimester. Eight (72%) women and seven (64%) infants experienced severe or life-threatening adverse events or outcomes that were unlikely to be related to levofloxacin. CONCLUSIONS: Levofloxacin AUC0-12 was lower in the second trimester than the third trimester of pregnancy and the postpartum period, but exposures overall were within target ranges. Further research is warranted to explore the clinical significance of these findings.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Hughes JA, Pinilla M, Brooks KM, et al. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clin Pharmacokinet. 2025. PMID: 40155501. doi:10.1007/s40262-025-01498-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。